ProCE Banner Series

Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers

In this 1-hour roundtable webinar, expert faculty will join us live from Chicago to discuss the latest data on HER2 testing and targeted therapies in patients with HER2-positive gastroesophageal cancers. Don’t miss the opportunity to get your pressing questions answered. Register now!

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with gastrointestinal malignancies. This educational program is also intended to reach patients with GI cancer and their caregivers.

All Events

Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers

Past Events

June

01

2024

6:30 AM - 7:30 AM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Jaffer A. Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Nataliya Uboha, MD, PhD

Faculty Leader for Early Phase Oncology Therapeutics Program
Associate Professor, Department of Medicine
Section of Hematology & Oncology
University of Wisconsin
Madison, Wisconsin

ProCE Banner Faculty
Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to educate oncologists and other healthcare professionals, patients, and caregivers on recent developments in the treatment of gastric and GEJ cancers to optimally individualize therapy. 

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who care for patients with gastrointestinal malignancies. This educational program is also intended to reach patients with GI cancer and their caregivers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the importance of biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-specific, disease-specific, and treatment-specific factors to aid in the development of individualized management plans for all patients with HER2-positive gastric/GEJ cancers
  • Plan evidence-based and expert-recommended therapeutic sequencing strategies for patients with HER2-positive gastric/GEJ cancers
  • Implement strategies incorporating the patient and multidisciplinary care team in the effective identification and management of treatment-related adverse events related to novel therapies for HER2-positive gastric/GEJ cancers
  • Identify patients most likely to benefit from enrollment on clinical trials with novel HER2-targeting therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from AstraZeneca.